SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) - Get Report today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020.
In advance of the virtual conference and investor meetings, a pre-recorded fireside chat with Saundra Pelletier, CEO of Evofem Biosciences, will be made available on Monday, November 23 at 10:00 AM Eastern Time. Interested parties may access the fireside chat by visiting the
About Evofem Biosciences
Evofem Biosciences, Inc., (EVFM) - Get Report is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate) , is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ' EVOGUARD ,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com .
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact Amy RaskopfEvofem Biosciences, Inc. email@example.com Mobile: (917) 673-5775
Media Contact Ellen ThomasEvofem Biosciences, Inc. firstname.lastname@example.org Mobile: (718) 490-3248
View original content to download multimedia: http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare-conference-301178010.html
SOURCE Evofem Biosciences, Inc.